| 0.3044 -0.014 (-4.28%) | 11-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.59 | 1-year : | 0.75 |
| Resists | First : | 0.51 | Second : | 0.64 |
| Pivot price | 0.38  |
|||
| Supports | First : | 0.28 | Second : | 0.24 |
| MAs | MA(5) : | 0.3 |
MA(20) : | 0.42 |
| MA(100) : | 0.67 |
MA(250) : | 1.21 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 7.5 |
D(3) : | 5.7 |
| RSI | RSI(14): 28 |
|||
| 52-week | High : | 3.06 | Low : | 0.28 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ICU ] has closed above bottom band by 25.7%. Bollinger Bands are 0.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.35 - 0.35 | 0.35 - 0.35 |
| Low: | 0.3 - 0.3 | 0.3 - 0.3 |
| Close: | 0.3 - 0.3 | 0.3 - 0.31 |
SeaStar Medical Holding Corporation, a medical device company, focuses on providing novel solutions and services to treat hyperinflammation and cytokine storm in critically ill patients. The company is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. It is developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure with and without LVAD; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is based in Denver, Colorado.
Thu, 20 Nov 2025
SeaStar Medical to Present at NobleCon21 Emerging Growth Equity Conference on December 3rd - Quiver Quantitative
Thu, 20 Nov 2025
SeaStar Medical to Present at Upcoming NobleCon21 Investor Conference - GlobeNewswire
Tue, 18 Nov 2025
SeaStar Medical Holding Corporation (NASDAQ:ICU) Q3 2025 Earnings Call Transcript - Insider Monkey
Mon, 17 Nov 2025
SeaStar Medical (Nasdaq: ICU) names CFO Michael Messinger, 25-year healthcare finance leader - Stock Titan
Mon, 17 Nov 2025
SeaStar Medical Announces Appointment of Michael Messinger as CFO - GlobeNewswire
Thu, 13 Nov 2025
SeaStar Medical (NASDAQ: ICU) raises $12.4M; QUELIMMUNE uptake, NEUTRALIZE-AKI at 146 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 34 (M) |
| Shares Float | 28 (M) |
| Held by Insiders | 0.8 (%) |
| Held by Institutions | 7 (%) |
| Shares Short | 617 (K) |
| Shares Short P.Month | 5,120 (K) |
| EPS | -1.86 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.38 |
| Profit Margin | 0 % |
| Operating Margin | -519.6 % |
| Return on Assets (ttm) | -156.2 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.02 |
| Sales Per Share | 0.02 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -15 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -0.17 |
| PEG Ratio | 0 |
| Price to Book value | -0.83 |
| Price to Sales | 13.55 |
| Price to Cash Flow | -0.68 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|